Compare Tango Therapeutics Inc. (TNGX) vs Valley National Bancorp Common Stock (VLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Valley National Bancorp Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B), while Valley National Bancorp Common Stock trades at $12.42 (market cap $6.86B). The key difference: Valley National Bancorp Common Stock is the larger of the two by market cap, and Valley National Bancorp Common Stock pays a 3.55% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Valley National Bancorp Common Stock for 6 Days on average.
| TNGX | VLY | |
|---|---|---|
Market Cap | $3.74B | $6.86B |
Volume | 3,438,781 | 6,537,186 |
Sector | Health | Financials |
52-Week High | $32.90 | $15.19 |
52-Week Low | $7.50 | $9.72 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.76B | $9.35B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Valley National Bancorp (VLY) trades at $12.53, down 0.87% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 10.61 and P/B of 0.91, indicating potential undervaluation. Recent earnings show mixed results with Q2 2026 missing estimates, but revenue growth remains solid at $2.2B for 2026. The company is actively expanding through acquisitions including Bluevine and Providence Financial to strengthen its deposit base and Chicago market presence.
Analyst consensus remains bullish with 62% buy ratings and a $16.50 price target, suggesting 32% upside potential. Key risks include integration challenges from recent acquisitions and higher operating expenses impacting margins. The upcoming Q3 2026 earnings report on October 22 will be crucial for validating growth trajectory amid current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Valley National Bancorp Common Stock
Valley National Bancorp is a financial holding company whose main subsidiary is Valley National Bank. It provides commercial, retail, trust, and investment services across several U.S. states.
Read more on VLY →
